Med BioGene continues development of cardiovascular disease profiling

By Lisa Kerner

Charlotte, N.C., Sept. 25 - Med BioGene Inc. said its Cardiovascular Disease Profiling System entered the development and validation phase to identify the genes, or biomarkers, that mark the presence of cardiovascular disease.

In addition, the company agreed to conduct a joint pilot project with Ottawa Heart Institute Research Corp. to develop and validate the genetic biomarkers in cardiovascular disease. Terms of the agreement are confidential.

Med BioGene is a Vancouver biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.